Work Ability After Diagnosis in Survivors of Hodgkin Lymphoma
Researchers sought to determine the work ability for survivors of Hodgkin lymphoma after diagnosis.
Researchers sought to determine the work ability for survivors of Hodgkin lymphoma after diagnosis.
Studies presented at the ASCO Annual Meeting 2023 highlighted new developments in lymphoma that could lead to changes in practice.
Researchers sought to determine whether BrECADD would be as effective as eBEACOPP in patients with advanced-stage classical Hodgkin lymphoma.
Intensified ABVD can improve outcomes, when compared with PET-adapted ABVD, in patients with previously untreated Hodgkin lymphoma, a phase 3 study suggests.
Researchers sought to determine whether adding brentuximab vedotin to nivolumab, doxorubicin, and dacarbazine would be a helpful first-line treatment for cHL.
Researchers sought to determine whether nivolumab would improve PFS compared with brentuximab vedotin in patients with advanced-stage cHL.
Researchers sought to determine whether combining nivolumab plus brentuximab vedotin would improve response rates in CAYAs with Hodgkin lymphoma.
Researchers sought to determine adherence to guidelines for oncologists utilizing PET-adapted strategies for patients with III/IV classic Hodgkin lymphoma.
Researchers studied the effect of preexisting rheumatoid arthritis on risk for mortality and immune-related adverse events among those receiving immune checkpoint inhibitors.
Pembrolizumab plus ICE chemotherapy appears effective as second-line treatment in patients with transplant-eligible Hodgkin lymphoma.